The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: Introduction and overview

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Rex, John H ^a,b   Wingard, John R ^c   Wenzel, Richard ^d   Herbrecht, Raoul ^e   Sobel, Jack ^f   Edwards Jr , John E ^g  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g St John's Cardiovascular Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBODY; ANTIFUNGAL AGENT; CYTOKINE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIFUNGAL PROPHYLAXIS; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CENTRAL VENOUS CATHETER; GASTROINTESTINAL MUCOSA; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE; LEUKEMIA; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; POLYPHARMACY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HUMANS; MYCOSES; PREVENTIVE MEDICINE; RESEARCH DESIGN;

EID: 12844254963     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421951     Document Type: Review

References (36)

1. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
2. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
4. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
5. Wheat LJ. Combination therapy for aspergillosis: Is it needed, and which combination? J Infect Dis 2003; 187:1831-3.
6. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
7. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002; 34:1386-90.
8. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis - disease spectrum, treatment practices, and outcomes. Medicine 2000; 79:250-60.
9. Marr KA. Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2001; 14:423-6.
10. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
11. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
12. Marr KA. Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39(Suppl 4):S170-5.
13. Dykewicz CA, Jaffe HW, Spira TJ, et al. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep 2000; 49:1-128.
14. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
15. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369-79.
16. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
17. Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004; 39(Suppl 4): S176-80.
18. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients - a meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611-25.
19. Herbrecht R, Neuville S, Letscher-Bru V, Natarajan-Ame S, Lortholary O. Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment. Drugs Aging 2000; 17:339-51.
20. Glasmacher A, Hahn C, Molitor E, Marklein G. Itraconazole for antifungal prophylaxis in neutropenic patients: a meta-analysis of 2181 patients [abstract J-681]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
21. Menichetti F. How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia. Clin Infect Dis 2004; 39(Suppl 4):S181-4.
22. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20:1531-4.
23. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
24. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-200.
25. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39(Suppl 4):S185-92.
26. Lipsett PA. Clinical trails of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004; 39(Suppl 4):S193-9.
27. Singh N. Antifungal prophylaxis in solid organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39(Suppl 4):S200-6.
28. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36:46-52.
29. Perfect JR, Dodds-Ashley E, Drew R. Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis 2004; 39(Suppl 4): S207-10.
30. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004; 39(Suppl4):S211-7.
31. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301:126-31.
32. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337:15-21.
33. Rex JH, Walsh TJ, Nettleman M, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001; 33:95-106.
34. Kullberg BJ, Lashof AMLO, Netea MG. Design of efficacy trials of cytokines in combination with antifungal drugs. Clin Infect Dis 2004; 39(Suppl 4):S218-23.
35. Sobel JD. Combination therapy for invasive mycoses - evaluation of past clinical trial design. Clin Infect Dis 2004; 39(Suppl4):S224-7
36. Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis 2004; 39(Suppl 4):S228-35.